Cargando…

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

AIM: To study the HER2 gene amplification or overexpression in patients with advanced gastric cancer (GC) and their association with patient characteristics and patient survival. PATIENTS AND METHODS: Tumour tissue samples from 148 patients with advanced GC were studied for HER2 by immunohistochemis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez-Martin, Carlos, Garralda, Elena, Echarri, M José, Ballesteros, Anabel, Arcediano, Alberto, Rodríguez-Peralto, José Luis, Hidalgo, Manuel, López-Ríos, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410298/ https://www.ncbi.nlm.nih.gov/pubmed/22569536 http://dx.doi.org/10.1136/jclinpath-2012-200774

Ejemplares similares

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas
por: Ansari, J, et al.
Publicado: (2011)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
por: Warneke, V. S., et al.
Publicado: (2013)

HER-2/neu and E-cadherin Expression and Microsatellite Instability in Gastric Dysplasia
por: Ahmadi, L, et al.
Publicado: (2011)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry
por: ZHU, GUANG-JUN, et al.
Publicado: (2014)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer
por: Basade, M., et al.
Publicado: (2018)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
por: Behrens, Hans-Michael, et al.
Publicado: (2015)

Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India
por: Nadaf, Asmanaz Saleem, et al.
Publicado: (2018)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings
por: Babashahi, Mashaallah, et al.
Publicado: (2013)

Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
por: Keay, Tyler, et al.
Publicado: (2013)

Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
por: Woo, Jennifer S., et al.
Publicado: (2016)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
por: Movagharnejad, Kourosh, et al.
Publicado: (2013)

The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9nnjnlh9qb307o20ent2pbefvi